ID | 1130 |
Name of the vaccine | MenHibrix |
Microbe | Bacteria |
Disease name | Meningococcal disease |
Name of bacteria | Neisseria meningitidis |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 6 weeks to 18 months |
Description of the vaccine | Meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine. |
Name of the manufacturer | GlaxoSmithKline Biologicals |
Name of the manufacturing country | Belgium |
Year of manufacture | 2012 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative diplococcus. |
Efficacy | NA |
Vaccine formulation | Solution for injection, lyophilized vaccine reconstituted with saline diluent. |
Dosage | Four doses (0.5 mL each) at 2, 4, 6, and 12 to 15 months. |
Mechanism of action | Production of bactericidal antibodies specific to the capsular polysaccharides of serogroups C and Y. |
Route of administration | Intramuscular |
Indications | Prevents invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. |
Export | Distributed by - GlaxoSmithKline |
Approval | US FDA |
Adjuvant | NA |
Repurposing | For Haemophilus influenzae type b. |
Side effects of vaccine | Injection site pain, redness, swelling, irritability, drowsiness, loss of appetite and fever. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/83688/download |
Other name | NA |
Additional Links | NA
|